Company news

DiaSorin S.p.A. news in 2026

DiaSorin S.p.A.'s news releases, calls and decks from 2026, newest first.

View company

DiaSorin S p A Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay

May 19, 2026

DiaSorin S p A Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President

May 4, 2026

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024

March 20, 2026

DiaSorin S p A signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform

March 19, 2026

DiaSorin S p A introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN

February 24, 2026

DiaSorin S p A submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver

February 3, 2026

DiaSorin S p A has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL

January 29, 2026

DiaSorin S p A signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel

January 26, 2026

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer.

January 22, 2026

Decks in 2026